Presentations highlight cutting-edge research in mitochondrial and neurodegeneration medicine, neurodegeneration, ...

Others have created a crisis out of an unpolitical poster that supports the basic sentiment ‘Everyone is Welcome’ in this ...

NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer ...

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

Trial-in-progress posters to be featured at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress - - FOG-001, first and only direct inhibitor of ß-cateninTCF4, monotherapy and combinati ...

Harlan County, Kentucky, had a drug overdose rate two times the national average. Through funding and community programs, ...

Press Release Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on ...

Imane Khelif is preparing to return to competitive women’s boxing in Eindhoven next month, threatening another major ...

EIK1003-001 (Abstract # CT197): A first-in-human, Phase 1/2 dose escalation, dose-optimization, and dose-expansion trial of PARP1-selective inhibitor EIK1003 in patients with advanced solid tumors.

Compugen Ltd. (NASDAQ: CGEN) Q1 2025 Earnings Call Transcript May 19, 2025 Compugen Ltd. misses on earnings expectations.